[Secondary tumors in hemoblastoses during cytostatic treatment].
D000310:Adrenal Gland Neoplasms / Q000139:chemically induced; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001984:Bronchial Neoplasms / Q000139:chemically induced; D002066:Busulfan / Q000009:adverse effects; D002277:Carcinoma / Q000139:chemically induced; D002699:Chlorambucil / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004407:Dysgerminoma / Q000139:chemically induced; D005260:Female; D005706:Gallbladder Neoplasms / Q000139:chemically induced; D006392:Hemangioma, Cavernous / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000139:chemically induced; D007822:Laryngeal Neoplasms / Q000139:chemically induced; D007938:Leukemia / Q000188:drug therapy; D008067:Lipoma / Q000139:chemically induced; D008113:Liver Neoplasms / Q000139:chemically induced; D008206:Lymphatic Diseases / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced*; D009463:Neuroma / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000139:chemically induced; D010212:Papilloma / Q000139:chemically induced; D010954:Plasmacytoma / Q000188:drug therapy; D012004:Rectal Neoplasms / Q000139:chemically induced; D013223:Statistics as Topic; D013724:Teratoma / Q000139:chemically induced; D013964:Thyroid Neoplasms / Q000139:chemically induced; D014228:Triaziquone / Q000009:adverse effects; D014520:Urethane / Q000009:adverse effects; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
D000970:Antineoplastic Agents; D002699:Chlorambucil; D014520:Urethane; D003520:Cyclophosphamide; D014228:Triaziquone; D002066:Busulfan
Zweittumoren bei Hämoblastosen unter zytostatischer Therapie.